We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

IBA Cooperates with Philips to Create Patient-Centric Proton Therapy Centers

By MedImaging International staff writers
Posted on 16 May 2011
Print article
IBA Group (Prague, Czech Republic), a developer of advanced cancer diagnosis and therapy technologies, and Philips Healthcare (Best, The Netherland) announced that they have entered into an agreement to create state-of-the-art patient-centric proton therapy centers.

IBA and Philips presented their plans together at the European Society of Therapeutic Radiology and Oncology (ESTRO) anniversary congress in London (UK) on May 8-12, 2011, and the Particle Therapy Cooperative Group (PTCOG) conference in Philadelphia (PA, USA) on May 8-14, 2011.

This cooperation is an important milestone in creating meaningful oncology systems for caregivers, patients, and their families who are in a very stressful situation. The complete center design is based on a thorough understanding of all emotional and physical aspects of patient care. From the moment they enter the center up to their final treatment, the patient is surrounded by light, image, and sound, making the treatment experience as calming and transparent as possible, while helping caregivers to work more efficiently.

The IBA-Philips "turnkey" proton center concept is the first of its kind, and is initially being developed for the Middle East market, with subsequent plans to expand its use globally. Named Proteus TK2, the IBA-Philips center design encompasses all elements necessary to build a complete proton therapy center. This includes the building exterior and interior architecture, two IBA proton therapy treatment rooms, Philips Ambient Experience Design solutions, Philips computed tomography (CT), CT SIM (simulation), magnetic resonance (MR) imaging systems, and patient monitoring equipment.

"This joint approach combines the strength of both companies that believe in a true people-focused solution, which makes this concept extremely attractive for those wanting to add proton therapy to their cancer fighting therapies," said Pierre Mottet, chief executive officer of IBA.

Dr. Eric Silfen, chief medical officer, Philips Healthcare added, "We are very proud to work together with IBA Group, a global leader in the proton technology market. Philips is committed to simplifying oncology care for a patient group that is still growing around the world."

Philips is a market leader in cardiac care, acute care, and home healthcare, energy-efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being.

IBA develops and markets technologies, pharmaceuticals, and customized solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Related Links:
IBA Group
Philips Healthcare

Computed Tomography System
Aquilion ONE / INSIGHT Edition
Ultrasonic Pocket Doppler
SD1
New
Needle Guide Disposable Kit
Verza
New
Biopsy Software
Affirm® Contrast

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more